Director/PDMR Shareholding

RNS Number : 8834Y

ConvaTec Group PLC

17 May 2021

 

17 May 2021

ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding

The Company has been notified of the following transactions by Persons Discharging Managerial Responsibility ("PDMR") in ordinary shares of 10 pence each in the share capital of the Company ("Shares").

On 13 May 2021, Frank Schulkes, Chief Financial Officer and a PDMR, received 52 Shares at £2.2284 per share under the terms of the Dividend Reinvestment Plan, operated by the Company's registrars for employees holding shares within its Share Plan Account. Mr Schulkes' resulting shareholding is 169,155 Shares.

Further, on the same day, Rick Anderson, Non-Executive Director and a PDMR, received 1136 Shares at £1.97 per share under the Scrip Dividend Scheme. Mr Anderson's resulting shareholding is 210,273 Shares.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Frank Schulkes
2	Reason for the notification
a)	Position/Status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ConvaTec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 10p each in ConvaTec Group Plc ("Shares") GB00BD3VFW73
b)	Nature of the transaction	Receipt of Shares under the terms of the Dividend    Reinvestment Plan operated by the Company's registrars for employees holding shares within its Share Plan Account.
c)	Price(s) and volume(s)	Price(s) £2.2284	Volume(s) 52
d)	Aggregated information - Aggregated volume  - Price	N/A N/A
e)	Date of the transaction	13 May 2021
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Rick Anderson
2	Reason for the notification
a)	Position/Status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ConvaTec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 10p each in ConvaTec Group Plc ("Shares") GB00BD3VFW73
b)	Nature of the transaction	Receipt of Shares under Scrip Dividend Scheme
c)	Price(s) and volume(s)	Price(s) £1.97	Volume(s) 1136
d)	Aggregated information - Aggregated volume  - Price	N/A N/A
e)	Date of the transaction	13 May 2021
f)	Place of the transaction	Outside a trading venue

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations, ConvaTec   [phone]

[e-mail]

Media

Buchanan: Charles Ryland / Chris Lane/ Hannah Ratcliff      [phone]         

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit  www.convatecgroup.com

 

END

 

 

DSHFLFVVELIDLIL